Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

Solid Neoplasms Clinical Trial

Official title:
Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Solid Neoplasms

Clinical Trial Details

NCT number	NCT03364049
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 1
Start date	December 6, 2017
Completion date	October 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04078295` - A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor	Phase 1/Phase 2
Withdrawn	`NCT02896049` - Celsius TCS Hyperthermia System PMCF Trial
Active, not recruiting	`NCT03833700` - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)	Phase 1
Recruiting	`NCT04407676` - Improving Informed Consent for Early Phase Anti-Cancer Trials	N/A
Recruiting	`NCT04420884` - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT01543282` - Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles	N/A